• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Soleo Health to administer Givlaari injections

March 10, 2021 By Sean Whooley

Soleo HealthSoleo Health announced that it joined the treatment center directory for Givlaari and can now administer it for adults with AHP.

Givlaari, managed by Alnylam Pharmaceuticals (NSDQ:ALNY), is the first FDA-approved treatment for acute hepatic porphyria (AHP) in adults. The once-monthly injection for subcutaneous use reduces the levels of neurotoxins associated with AHP attacks and other AHP disease manifestations in adults, according to a news release.

Frisco, Texas-based Soleo Health can now offer Givlaari injections for subcutaneous use in patients’ homes or at one of its ambulatory infusion centers. The company also offers its proprietary clinical outcomes program, SoleMetrics, to collect and produce real-world data over time to gather outcomes throughout the patient’s journey with Givlaari.

“We are once again expanding our portfolio of infusible and injectable specialty pharmaceuticals to elevate our levels of quality patient care and therapeutic service offerings. Our role in the administration of Givlaari complements the many other rare or ultra-rare drug distribution products and personalized care we provide,” Soleo Health CEO Drew Walk said in the release. “Soleo Health has established an expertise in leveraging SoleMetrics for these specialty pharmaceuticals and will do the same for those adults with AHP through the collection and analysis of critical outcomes data.

“Broadening our therapeutic portfolio continues to differentiate Soleo Health in the serving of patients with rare and ultra-rare diseases.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Alnylam Pharmaceuticals, Soleo Health

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS